Companies · Biotechnology

Iantrek, Inc.

WHITE PLAINS · Biotechnology

Diligence memoA one-page analyst read on Iantrek, Inc. — recommendation, valuation, rhythm, risks.
$58.2M
Total raised · real
4
Rounds
12.5×
Latest step-up
Top 17%
Sector rank · raised
Series B
Latest stage · inferred · Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Iantrek, Inc. looks over-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.97× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era.
Active
  • Last raise 10 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Iantrek, Inc. is one of 4291 Biotechnology companies tracked from WHITE PLAINS. By capital raised it ranks in the upper tier (ahead of 84% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
21
Investors (latest)
2025-08-19
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2020-10-16 Raised $5.2M (real) Modeled valuation $164M (est)$5.2M$164MSeries A2020Series B · 2022-08-04 Raised $15M (real) Modeled valuation $249M (est)$15M$249MSeries B2022Series B · 2025-02-14 Raised $2.8M (real) Modeled valuation $15M (est)$2.8M$15MSeries B2025Series B · 2025-08-19 Raised $35M (real) Modeled valuation $152M (est)$35M$152MSeries B2025+$15M+$2.8M+$35MCumulative $58M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.2M · 2020
Series B$15.4M · 2022
Series B extension$2.8M · 2025
Series B extension$34.7M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$152.2M
Base estimate est.
$69.5M
Conservative case
$219.3M
Upside case
$193.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $163.8M · 2020-10-162020Series B · modeled $249.1M · 2022-08-04Series B · modeled $15.2M · 2025-02-14Series B · modeled $152.2M · 2025-08-192025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
0.9 yr
Elapsed time used
0.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
19 mo
Avg between rounds
$12.0M/yr
Capital velocity
5.7 yr
On record since
2020
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 8.1× above median
This company$58.2M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 2.0× above median
This company$34.7M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 2.4× above median
This company$152.2M
Sector median$64.2M

Raised more than 84% of sector peers (real $). Modeled value above 67% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #2 of 94.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)MarvelBiome, Inc. · Series B Raised $54.9M · modeled $163.1M (est)Dualitas Therapeutics, Inc. · Series B Raised $32.6M · modeled $150.2M (est)Antares Therapeutics, Inc. · Series B Raised $70.0M · modeled $149.6M (est)OrthoBio Therapeutics, Inc. · Series B Raised $31.4M · modeled $147.3M (est)Medcura, Inc. · Series B Raised $40.9M · modeled $144.9M (est)Neurolutions Inc · Series B Raised $26.5M · modeled $144.7M (est)Renasant Bio, Inc. · Series B Raised $55.5M · modeled $143.9M (est)Caldera Therapeutics, Inc. · Series B Raised $37.5M · modeled $139.0M (est)VitriVax, Inc. · Series B Raised $29.4M · modeled $136.7M (est)DiaMedica Therapeutics Inc. · Series B Raised $110.4M · modeled $136.1M (est)OmniAb, Inc. · Series B Raised $30.0M · modeled $130.4M (est)Iantrek, Inc. (this company) Raised $58.2M · modeled $152.2M (est)Iantrek, Inc.
CompanyStageRaised · realValue · estvs peer med.
MarvelBiome, Inc.Series B$54.9M$163.1M2.11×
Iantrek, Inc. this companySeries B$58.2M$152.2M1.97×
Dualitas Therapeutics, Inc.Series B$32.6M$150.2M1.94×
Antares Therapeutics, Inc.Series B$70.0M$149.6M1.93×
OrthoBio Therapeutics, Inc.Series B$31.4M$147.3M1.90×
Medcura, Inc.Series B$40.9M$144.9M1.87×
Neurolutions IncSeries B$26.5M$144.7M1.87×
Renasant Bio, Inc.Series B$55.5M$143.9M1.86×
Caldera Therapeutics, Inc.Series B$37.5M$139.0M1.80×
VitriVax, Inc.Series B$29.4M$136.7M1.77×
DiaMedica Therapeutics Inc.Series B$110.4M$136.1M1.76×
OmniAb, Inc.Series B$30.0M$130.4M1.68×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.2M2020-10-16$23.7M$163.8M90%
Series B$15.4M2022-08-04$85.6M$249.1M90%
Series B$2.8M2025-02-14$15.4M$15.2M90%
Series B$34.7M2025-08-19$193.0M$152.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.2M2020-10-16
    • First recorded raise — entered as Series A.
    • 29 investors on this round.
  2. Series B$15.4M2022-08-04
    • Raised again after 22 mo — slower than the ~14 mo sector norm.
    • Round 3.0× larger than the prior — scaling up.
    • 25 investors on this round.
  3. Series B$2.8M2025-02-14
    • Raised again after 30 mo — slower than the ~14 mo sector norm.
    • Round 5.5× smaller than the prior — bridge or down round.
    • 4 investors on this round.
  4. Series B$34.7M2025-08-19
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 12.5× larger than the prior — scaling up.
    • 21 investors on this round.
Intelligence
2027 ~Q1
Modeled next raise · ~19mo cadence
$104.2M
Modeled next size est.range $67.8M$166.8M
12.5×
Last step-up
$12.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Stephen Bloch14 other2020-10
Marc-Andre Marcotte5 other2025-02
Tsontcho Ianchulev4 other2020-10
James Mazzo3 other2020-10
Casey K. Tansey2 other2025-08
Andrew Corley1 other2020-10
Jeffry K. Weinhuff1 other2020-10
Michael Haydin1 other2020-10
Adam K. Szaronos2025-08
Farrell George Tyson2022-08
Farrell Tyson2025-02
James George Mazzo2022-08
Jeffrey K. Weinhuff2022-08
Marc-Andre George Marcotte2022-08
Michael George Haydin, IV2022-08
Robert K. Weinreb2020-10
Todd K. Sone2025-08
Tsontcho George Ianchulev2022-08
Registry & provenance

Iantrek, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1829982
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Aquesys IncBiotechnologySeries B$49.5M$1.2Bnetwork1 shared operator · same sector · same stage
EvolveImmune Therapeutics Holding Company, LLCBiotechnologySeries B$85.8M$124.8Mnetwork1 shared operator · same sector · same stage
Liquidia Technologies IncBiotechnologySeries B$86.7M$890.0Mnetwork1 shared operator · same sector · same stage
Liquidia CorpBiotechnologySeries B$21.7M$616.1Mnetwork1 shared operator · same sector · same stage
Consano Bio, Inc.BiotechnologySeries B$59.6M$120.8Msame sector · same stage
SELLAS Life Sciences Group, Inc.BiotechnologySeries B$60.6M$148.6Msame sector · same stage
Renasant Bio, Inc.BiotechnologySeries B$55.5M$143.9Msame sector · same stage
Judo Bio Inc.BiotechnologySeries B$55.0M$172.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
iTolerance, Inc.BiotechnologySeries B$423.5M84%
Codiak BioSciences, Inc.BiotechnologySeries C$3.1B84%
X-Biomedical Inc.BiotechnologyPre-Seed$23.5M84%
IDBiologics, Inc.BiotechnologySeries A$155.4M84%
Invisimask Technologies Ltd.BiotechnologySeed$32.1M84%
VeriSkin, Inc.BiotechnologyPre-Seed$30.9M83%
ORI, Inc. / UTBiotechnologySeed$9.2M83%
Xenetic Biosciences, Inc.BiotechnologySeries A$5.9M83%
Frequently asked
How much funding has Iantrek, Inc. raised?
Iantrek, Inc. has raised approximately $58.2M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Iantrek, Inc.'s estimated valuation?
Provath's modeled valuation for Iantrek, Inc. is approximately $152.2M (modeled range $69.5M–$219.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Iantrek, Inc. at?
Iantrek, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Aug 19.
What does Iantrek, Inc. do and where is it based?
Iantrek, Inc. operates in the Biotechnology sector, based in WHITE PLAINS.
Explore related

See where Iantrek, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Iantrek, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.